Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Accenture
Merck
Cerilliant
Fuji
Moodys
Deloitte
Dow

Generated: October 20, 2018

Drug Patent Expirations and Generic Entry Opportunities
2018 - 2019

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Drug Patent Expirations and Generic Entry Opportunities 2018 - 2019" DrugPatentWatch.com thinkBiotech, 2018 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology employed here is described in this blog post.
FORTEO

Generic name: teriparatide recombinant human
Patent Expiration / Generic Entry Opportunity December 08, 2018
Generic Entry Controlled by: Patent 6,770,623

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

ACTONEL WITH CALCIUM (COPACKAGED)

Generic name: calcium carbonate; risedronate sodium
Patent Expiration / Generic Entry Opportunity December 10, 2018
Generic Entry Controlled by: Patent 6,165,513

ACTONEL WITH CALCIUM (COPACKAGED) is a drug marketed by Warner Chilcott. There are five patents protecting this drug. There has been litigation on patents covering ACTONEL WITH CALCIUM (COPACKAGED)

The generic ingredient in ACTONEL WITH CALCIUM (COPACKAGED) is calcium carbonate; risedronate sodium. There are two hundred and seventy-eight drug master file entries for this API. Additional details are available on the calcium carbonate; risedronate sodium profile page.

MOZOBIL

Generic name: plerixafor
Patent Expiration / Generic Entry Opportunity December 10, 2018
Generic Entry Controlled by: Patent RE42152

MOZOBIL is a drug marketed by Genzyme. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering MOZOBIL

See drug price trends for MOZOBIL.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the plerixafor profile page.

PYLERA

Generic name: bismuth subcitrate potassium; metronidazole; tetracycline
Patent Expiration / Generic Entry Opportunity December 14, 2018
Generic Entry Controlled by: Patent 6,350,468

PYLERA is a drug marketed by Allergan Sales Llc. There is one patent protecting this drug and one Paragraph IV challenge.

See drug price trends for PYLERA.

The generic ingredient in PYLERA is bismuth subcitrate potassium; metronidazole; tetracycline. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bismuth subcitrate potassium; metronidazole; tetracycline profile page.

ELIDEL

Generic name: pimecrolimus
Patent Expiration / Generic Entry Opportunity December 26, 2018
Generic Entry Controlled by: Patent 6,423,722

Drug Price Trends for ELIDEL
ELIDEL is a drug marketed by Valeant Bermuda. There is one patent protecting this drug. There has been litigation on patents covering ELIDEL

See drug price trends for ELIDEL.

The generic ingredient in ELIDEL is pimecrolimus. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pimecrolimus profile page.

FOSAMAX PLUS D

Generic name: alendronate sodium; cholecalciferol
Patent Expiration / Generic Entry Opportunity January 17, 2019
Generic Entry Controlled by: Patent 5,994,329

Drug Price Trends for FOSAMAX PLUS D
FOSAMAX PLUS D is a drug marketed by Merck. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering FOSAMAX PLUS D

See drug price trends for FOSAMAX PLUS D.

The generic ingredient in FOSAMAX PLUS D is alendronate sodium; cholecalciferol. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the alendronate sodium; cholecalciferol profile page.

SYMLIN

Generic name: pramlintide acetate
Patent Expiration / Generic Entry Opportunity March 16, 2019
Generic Entry Controlled by: Patent 5,686,411

SYMLIN is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug.

See drug price trends for SYMLIN.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pramlintide acetate profile page.

TECFIDERA

Generic name: dimethyl fumarate
Patent Expiration / Generic Entry Opportunity April 01, 2019
Generic Entry Controlled by: Patent 6,509,376

TECFIDERA is a drug marketed by Biogen Idec Inc. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering TECFIDERA

See drug price trends for TECFIDERA.

The generic ingredient in TECFIDERA is dimethyl fumarate. There are seventy-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dimethyl fumarate profile page.

FLECTOR

Generic name: diclofenac epolamine
Patent Expiration / Generic Entry Opportunity April 13, 2019
Generic Entry Controlled by: Patent 5,607,690

Drug Price Trends for FLECTOR
FLECTOR is a drug marketed by Inst Biochem. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering FLECTOR

See drug price trends for FLECTOR.

The generic ingredient in FLECTOR is diclofenac epolamine. There are forty-seven drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the diclofenac epolamine profile page.

BEVESPI AEROSPHERE

Generic name: formoterol fumarate; glycopyrrolate
Patent Expiration / Generic Entry Opportunity April 25, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

BEVESPI AEROSPHERE is a drug marketed by Astrazeneca Pharms. There are six patents protecting this drug.

See drug price trends for BEVESPI AEROSPHERE.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

OTOVEL

Generic name: ciprofloxacin hydrochloride; fluocinolone acetonide
Patent Expiration / Generic Entry Opportunity April 29, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for OTOVEL
OTOVEL is a drug marketed by Laboratorios Salvat. There is one patent protecting this drug.

See drug price trends for OTOVEL.

The generic ingredient in OTOVEL is ciprofloxacin hydrochloride; fluocinolone acetonide. There are thirty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciprofloxacin hydrochloride; fluocinolone acetonide profile page.

BYVALSON

Generic name: nebivolol hydrochloride; valsartan
Patent Expiration / Generic Entry Opportunity June 03, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for BYVALSON
BYVALSON is a drug marketed by Allergan Sales Llc. There are two patents protecting this drug and one Paragraph IV challenge.

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

KOVANAZE

Generic name: oxymetazoline hydrochloride; tetracaine hydrochloride
Patent Expiration / Generic Entry Opportunity June 29, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

KOVANAZE is a drug marketed by St Renatus. There are three patents protecting this drug.

The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this API. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.

FIRAZYR

Generic name: icatibant acetate
Patent Expiration / Generic Entry Opportunity July 15, 2019
Generic Entry Controlled by: Patent 5,648,333

FIRAZYR is a drug marketed by Shire Orphan Therap. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering FIRAZYR

See drug price trends for FIRAZYR.

The generic ingredient in FIRAZYR is icatibant acetate. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the icatibant acetate profile page.

NOXAFIL

Generic name: posaconazole
Patent Expiration / Generic Entry Opportunity July 19, 2019
Generic Entry Controlled by: Patent 5,661,151

Drug Price Trends for NOXAFIL
NOXAFIL is a drug marketed by Merck Sharp Dohme and ScheringThere are eight patents protecting this drug and three Paragraph IV challenges. There has been litigation on patents covering NOXAFIL

See drug price trends for NOXAFIL.

The generic ingredient in NOXAFIL is posaconazole. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the posaconazole profile page.

TROXYCA ER

Generic name: naltrexone hydrochloride; oxycodone hydrochloride
Patent Expiration / Generic Entry Opportunity August 19, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

TROXYCA ER is a drug marketed by Pfizer Inc. There are two patents protecting this drug.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this API. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

YOSPRALA

Generic name: aspirin; omeprazole
Patent Expiration / Generic Entry Opportunity September 14, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

YOSPRALA is a drug marketed by Genus Lifesciences. There are five patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering YOSPRALA

See drug price trends for YOSPRALA.

The generic ingredient in YOSPRALA is aspirin; omeprazole. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the aspirin; omeprazole profile page.

CYSTARAN

Generic name: cysteamine hydrochloride
Patent Expiration / Generic Entry Opportunity October 02, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

CYSTARAN is a drug marketed by Leadiant Biosci Inc.

See drug price trends for CYSTARAN.

The generic ingredient in CYSTARAN is cysteamine hydrochloride. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

LUMASON

Generic name: sulfur hexafluoride lipid-type a microspheres
Patent Expiration / Generic Entry Opportunity October 10, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

LUMASON is a drug marketed by Bracco. There is one patent protecting this drug.

See drug price trends for LUMASON.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

SYNRIBO

Generic name: omacetaxine mepesuccinate
Patent Expiration / Generic Entry Opportunity October 26, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

SYNRIBO is a drug marketed by Teva Pharms Intl. There are two patents protecting this drug and one Paragraph IV challenge.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omacetaxine mepesuccinate profile page.

SIMBRINZA

Generic name: brimonidine tartrate; brinzolamide
Patent Expiration / Generic Entry Opportunity December 07, 2019
Generic Entry Controlled by: Patent 6,316,441

Drug Price Trends for SIMBRINZA
SIMBRINZA is a drug marketed by Novartis Pharms Corp. There are three patents protecting this drug.

See drug price trends for SIMBRINZA.

The generic ingredient in SIMBRINZA is brimonidine tartrate; brinzolamide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the brimonidine tartrate; brinzolamide profile page.

DUREZOL

Generic name: difluprednate
Patent Expiration / Generic Entry Opportunity December 13, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for DUREZOL
DUREZOL is a drug marketed by Novartis Pharms Corp. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering DUREZOL

See drug price trends for DUREZOL.

The generic ingredient in DUREZOL is difluprednate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the difluprednate profile page.

Clients in 66 Countries

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
US Department of Justice
McKinsey
Baxter
Argus Health
Medtronic
US Army
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.